Dupilumab
Modify Date: 2024-01-02 08:26:56
Dupilumab structure
|
Common Name | Dupilumab | ||
|---|---|---|---|---|
| CAS Number | 1190264-60-8 | Molecular Weight | 99999.99999 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C6512H10066N1730O2052S46 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DupilumabDupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis[1]. |
| Name | Dupilumab |
|---|
| Description | Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis[1]. |
|---|---|
| Related Catalog | |
| Target |
IL-4 and IL-13 signaling[1] |
| In Vitro | Dupilumab suppressed mRNA expressions of genes related to activation of T cells, DCs, eosinophils, inflammatory pathways, and TH2-inducing chemokines in skin lesions. No significant reduction in IL-17A or IL-22 levels is detected, but large reductions in expression of IL-17–related genes, such as elafin (PI3), IL23p19/IL23A, and S100A8 and trends for suppression (CXCL1 and S100A7) are found with 300 mg of Dupilumab[1]. Major suppressions of hyperplasia-related genes (eg, K16) and reductions in expression of S100A genes are evident with 300 mg of Dupilumab by using microarrays and qRT-PCR. The changes in other critical epidermal alterations in severe atopic dermatitis (AD) skin are also measured, including significant increases in claudin and lipid product levels with 300 mg of Dupilumab. A trend of dose-dependent increases in expression of differentiation genes (LOR and FLG) is observed after adjusting for suppression of epidermal hyperplasia, as demonstrated by K16 reductions with Dupilumab[1]. |
| References |
| Molecular Formula | C6512H10066N1730O2052S46 |
|---|---|
| Molecular Weight | 99999.99999 |
| Exact Mass | 99999.99999 |
| Storage condition | 2-8°C |